SACRAMENTO—Genentech Inc. and OSI Pharmaceuticals LLC will pay a combined $67 million to resolve allegations that they overstated the ability of the drug Tarceva to treat certain non-small cell lung cancer patients, the U.S. Attorney’s Office for the Northern District of California said Monday.
Genentech, based in South San Francisco, and OSI Pharmaceuticals of Farmingdale, New York, co-promoted Tarceva to doctors and health care providers between 2006 and 2011 as an effective treatment for the most common form of lung cancer. Federal prosecutors say that there is little evidence that Tarceva is effective unless recipients have never smoked or unless they have a mutation in a protein involved in the growth of cancer cells.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
